Trial · NCT03979209
Potential for Cortisol Suppression With the Use of High Volume Nasal Mometasone Irrigations in Varying Dosages.
NCT03979209, Phase 1, Completed, Rush University Medical Center; results first posted 2024-08-12
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Potential for Cortisol Suppression With the Use of High Volume Nasal Mometasone Irrigations in Varying Dosages. Trials, record NCT03979209. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03979209
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Potential for Cortisol Suppression With the Use of High Volume Nasal Mometasone Irrigations in Varying Dosages.
- NCT number
- NCT03979209
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 16 participants, actual
- Lead sponsor
- Rush University Medical Center
- Conditions
- Chronic Rhinosinusitis (Diagnosis)
- Interventions
- Nasal Mometasone Rinse
- First posted
- 2019-06-07
- Last updated
- 2024-08-12
- Results first posted
- 2024-08-12
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Morning "AM" Serum Cortisol Level | Morning (AM) at week 12, | The potential for cortisol suppression will be assessed with "AM" cortisol level after continuous nasal mometasone irrigation. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Morning AM Serum Cortisol Level | Morning (AM) at week 12, | The morning AM cortisol levels were added for each participant in the arms. | mcg/dL | MEDIAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Morning AM Serum Cortisol Level | Mometasone 1mg | 17.35 | Full Range 13.1 to 21.6 | mcg/dL | |
| Morning AM Serum Cortisol Level | Mometasone 2mg | 14.48 | Full Range 9.3 to 24.8 | mcg/dL |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Mometasone 1mg | 2 | |
| Overall Study | STARTED | Mometasone 2mg | 14 | |
| Overall Study | STARTED | Mometasone 4mg | 0 | |
| Overall Study | COMPLETED | Mometasone 1mg | 2 | |
| Overall Study | COMPLETED | Mometasone 2mg | 14 | |
| Overall Study | COMPLETED | Mometasone 4mg | 0 | |
| Overall Study | NOT COMPLETED | Mometasone 1mg | 0 | |
| Overall Study | NOT COMPLETED | Mometasone 2mg | 0 | |
| Overall Study | NOT COMPLETED | Mometasone 4mg | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Mometasone 1mg | 0 | 2 |
| Total, all-cause mortality | Mometasone 2mg | 0 | 14 |
| Total, other adverse events | Mometasone 1mg | 0 | 2 |
| Total, other adverse events | Mometasone 2mg | 0 | 14 |
| Total, serious adverse events | Mometasone 1mg | 0 | 2 |
| Total, serious adverse events | Mometasone 2mg | 0 | 14 |
Source ClinicalTrials.gov
Papers9
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Mometasone 1mg vs Mometasone 2mg: deaths from any cause | Trial comparisons |
| Mometasone 1mg vs Mometasone 2mg: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03979209
GET https://conductscience.org/api/trials/v1/NCT03979209/registered